Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.
Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.
Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.
(The Hill) – Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, ...
2don MSN
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or ...
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...
Down with Rybelsus! No, this isn’t a line from "1984," but rather the new message from Novo Nordisk for its first Rybelsus ad of 2022. One of the biggest issues facing new medicines like Rybelsus, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results